Ensign Peak Advisors Inc acquired a new stake in Altimmune, Inc. (NASDAQ:ALT – Get Rating) during the 3rd quarter, Holdings Channel.com reports. The fund acquired 57,300 shares of the company’s stock, valued at approximately $732,000.
Several other large investors also recently modified their holdings of ALT. JPMorgan Chase & Co. raised its position in shares of Altimmune by 65.8% in the first quarter. JPMorgan Chase & Co. now owns 307,589 shares of the company’s stock valued at $1,873,000 after purchasing an additional 122,021 shares during the period. MetLife Investment Management LLC raised its position in shares of Altimmune by 65.5% in the first quarter. MetLife Investment Management LLC now owns 21,184 shares of the company’s stock valued at $129,000 after purchasing an additional 8,385 shares during the period. Canada Pension Plan Investment Board bought a new position in shares of Altimmune in the first quarter valued at about $1,108,000. Vanguard Group Inc. raised its position in shares of Altimmune by 4.8% in the first quarter. Vanguard Group Inc. now owns 1,816,915 shares of the company’s stock valued at $11,065,000 after purchasing an additional 83,160 shares during the period. Finally, XTX Topco Ltd raised its position in shares of Altimmune by 33.2% in the first quarter. XTX Topco Ltd now owns 19,665 shares of the company’s stock valued at $120,000 after purchasing an additional 4,898 shares during the period. 93.69% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
Several research firms recently commented on ALT. Evercore ISI upped their price target on shares of Altimmune from $14.00 to $25.00 and gave the company an “outperform” rating in a research note on Wednesday, January 18th. HC Wainwright reaffirmed a “buy” rating and set a $50.00 target price on shares of Altimmune in a report on Thursday, March 9th. Finally, The Goldman Sachs Group started coverage on Altimmune in a research note on Thursday, December 1st. They issued a “buy” rating and a $20.00 price target for the company. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $29.13.
Altimmune Price Performance
Altimmune (NASDAQ:ALT – Get Rating) last released its quarterly earnings data on Tuesday, February 28th. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.09. The business had revenue of ($0.11) million for the quarter, compared to analyst estimates of $0.11 million. Altimmune had a negative return on equity of 44.02% and a negative net margin of 2,618.74%. As a group, sell-side analysts expect that Altimmune, Inc. will post -1.94 earnings per share for the current year.
Insiders Place Their Bets
In other news, Director Wayne Pisano sold 20,000 shares of the business’s stock in a transaction dated Thursday, December 22nd. The stock was sold at an average price of $15.01, for a total transaction of $300,200.00. Following the sale, the director now directly owns 8,498 shares in the company, valued at $127,554.98. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 3.19% of the company’s stock.
Altimmune Company Profile
Altimmune, Inc is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH.
- Get a free copy of the StockNews.com research report on Altimmune (ALT)
- First Republic: First Rate Risk or Time To Buy?
- These Hedge Funds Are Getting Crushed By SVB
- Buy The Dip In The Charles Schwab Corporation
- ZIM Integrated Shipping Services: Up 15% But Don’t Chase It
- FedEx Is A Buy Going Into Earnings
Want to see what other hedge funds are holding ALT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Altimmune, Inc. (NASDAQ:ALT – Get Rating).
Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with MarketBeat.com's FREE daily email newsletter.